← All trials
NCT05635201
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Dec 2, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daegu Catholic UniversityLead sponsor
- Daegu Catholic UniversityOverall official - principal investigator
- Daegu Catholic UniversityReponsible party - principal investigator
- Hana Pharmaceutical Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.